Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10192995" target="_blank" >RIV/00216208:11110/13:10192995 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00064165:_____/13:10192995
Výsledek na webu
<a href="http://dx.doi.org/10.1148/radiol.13122424" target="_blank" >http://dx.doi.org/10.1148/radiol.13122424</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1148/radiol.13122424" target="_blank" >10.1148/radiol.13122424</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis
Popis výsledku v původním jazyce
Purpose: To investigate the association between the development of thalamic and cortical atrophy and the conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndrome (CIS). Materials and Methods: This prospective study was approved by the institutional review board. Informed consent was given by 216 CIS patients, and patients were treated with 30 mu g of intramuscular interferon beta 1a once a week. They were assessed with a magnetic resonance (MR) imaging examination at baseline, 6 months, 1 year, and 2 years. Patients were evaluated within 4 months of an initial demyelinating event, had two or more brain lesions on MR images, and had two or more oligoclonal bands in cerebrospinal fluid. MR imaging measuresof progression included cumulative number and volume of contrast agent-enhanced (CE) new and enlarged T2 lesions, and changes in whole-brain, tissue-specific global, and regional gray matter volumes. Regression and mixed-effect model ana
Název v anglickém jazyce
Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis
Popis výsledku anglicky
Purpose: To investigate the association between the development of thalamic and cortical atrophy and the conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndrome (CIS). Materials and Methods: This prospective study was approved by the institutional review board. Informed consent was given by 216 CIS patients, and patients were treated with 30 mu g of intramuscular interferon beta 1a once a week. They were assessed with a magnetic resonance (MR) imaging examination at baseline, 6 months, 1 year, and 2 years. Patients were evaluated within 4 months of an initial demyelinating event, had two or more brain lesions on MR images, and had two or more oligoclonal bands in cerebrospinal fluid. MR imaging measuresof progression included cumulative number and volume of contrast agent-enhanced (CE) new and enlarged T2 lesions, and changes in whole-brain, tissue-specific global, and regional gray matter volumes. Regression and mixed-effect model ana
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FH - Neurologie, neurochirurgie, neurovědy
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/NT13237" target="_blank" >NT13237: Klinické a paraklinické markery roztroušené sklerózy – korelace se současným stavem pacienta a predikce průběhu nemoci.</a><br>
Návaznosti
Z - Vyzkumny zamer (s odkazem do CEZ)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Radiology
ISSN
0033-8419
e-ISSN
—
Svazek periodika
268
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
11
Strana od-do
831-841
Kód UT WoS článku
000323419300024
EID výsledku v databázi Scopus
—